Fortrea Holdings FTRE
NASDAQ FTRE
$18.27 -0.35 (-1.85%)
As of: Sep 4, 2026 · 11:50 AM EDT

Fortrea Holdings (FTRE) Income towards Parent Company (2022 - 2026)

Fortrea Holdings' (FTRE) quarterly Income towards Parent Company came in at -$13.2 million in Q2 2026, up 44.07% on a QoQ basis from -$23.6 million in Q1 2026.

Analysis

Fortrea Holdings (FTRE) Income towards Parent Company (2022 - 2026) Analysis & Trends

Fortrea Holdings (FTRE) has 4 years of Income towards Parent Company data on file, last reported at -$13.2 million in Q2 2026.

  • Quarterly Income towards Parent Company changed N/A year-over-year to -$13.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$36.8 million (down 1215.15% YoY) and the FY2024 annual result came in at -$57.0 million, down 976.92% from the prior year.
  • Income towards Parent Company improved to -$13.2 million in Q2 2026, from -$23.6 million in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of $66.4 million in Q2 2022 to a low of -$39.1 million in Q2 2024.
  • A 4-year average of $2.0 million and a median of -$5.9 million in 2023 frame the typical range for Income towards Parent Company.
  • The widest YoY moves for Income towards Parent Company: up 315.25% in 2024, down 774.14% in 2024.
  • Tracing FTRE's Income towards Parent Company over 4 years: stood at -$13.6 million in 2022, then soared by 56.62% to -$5.9 million in 2023, then surged by 315.25% to $12.7 million in 2024, then sank by 203.94% to -$13.2 million in 2026.
  • The last three Income towards Parent Company figures came in at -$13.2 million (Q2 2026), -$23.6 million (Q1 2026), and $12.7 million (Q4 2024), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 140.21 Bn 132.36 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 86.04 Bn 78.05 Bn 3.93 Bn
3 Argenx Se 63.73 Bn 58.55 Bn 1.37 Bn
4 Moderna 57.59 Bn 52.46 Bn 52.00 Mn
5 Revolution Medicines 43.98 Bn 43.98 Bn -
6 BeOne Medicines 40.13 Bn 35.04 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.55 Bn 32.24 Bn 992.69 Mn
8 Royalty Pharma 28.60 Bn 27.77 Bn -
9 Insmed 27.70 Bn 26.54 Bn 358.27 Mn
10 Fortrea Holdings 1.73 Bn 1.56 Bn 139.20 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -13.20 Mn
Mar 31, 2026 -23.60 Mn
Dec 31, 2025 -32.50 Mn
Sep 30, 2025 -15.90 Mn
Jun 30, 2025 -374.90 Mn
Mar 31, 2025 -562.90 Mn
Dec 31, 2024 -61.20 Mn
Sep 30, 2024 -27.90 Mn
Jun 30, 2024 -138.40 Mn
Mar 31, 2024 -101.00 Mn
Dec 31, 2023 -54.50 Mn
Sep 30, 2023 -14.00 Mn
Jun 30, 2023 30.80 Mn
Mar 31, 2023 12.50 Mn
Dec 31, 2022 -13.60 Mn
Sep 30, 2022 60.60 Mn
Jun 30, 2022 66.40 Mn